BBA
GALT icon

Baker Bros. Advisors’s Galectin Therapeutics GALT Stock Holding History

Baker Bros. Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-300,000
Closed -$4.14M – 109
2014
Q2 		$4.14M Sell
300,000
-200,000
-40% -$2.49M 0.05% 76
2014
Q1 		$7.66M Buy
500,000
+399,400
+397% +$5.69M 0.1% 56
2013
Q4 		$813K Buy
+100,600
New +$929K 0.01% 90

Other funds holding GALT

CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Baker Bros. Advisors's GALT Position: Q3 2014 in Review

Baker Bros. Advisors sold out of Galectin Therapeutics (GALT) in Q3 2014, closing a stake of 300,000 shares — an estimated $4.14M sold.

Baker Bros. Advisors first reported a position in GALT in Q4 2013 and held it in 3 quarters. The position peaked at $7.66M in Q1 2014. 63 funds tracked by Wall St. Rank hold GALT as of Q3 2014.

  • Baker Bros. Advisors reported no remaining Galectin Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Baker Bros. Advisors sold 300,000 Galectin Therapeutics shares in Q3 2014, an estimated $4.14M.
  • Baker Bros. Advisors first reported a position in Galectin Therapeutics in Q4 2013 and held it in 3 quarters.
  • Baker Bros. Advisors's Galectin Therapeutics position peaked at $7.66M in Q1 2014.
  • 63 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2014.

Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.